Meningitis News and Research

Latest Meningitis News and Research

Young girls face increased risk of side effects after Gardasil vaccination

Younger girls are more likely than adult women to report side effects after receiving Gardasil, the human papillomavirus vaccine.

4 Apr 2012

New drive to prevent youngsters from inhaling second-hand smoke at home

There has a rise in the number of smokers despite the fewer public places at which to light up and one of the world's highest cigarette prices. Sales have hit a four-year high in 2009: 2.44 billion cigarettes, or 6.7 million a day. This was a 12-per-cent rise over 2008's figure of 2.17 billion sold; in 2005, it was 2.09 billion.

1 Apr 2012

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

26 Mar 2012

LSHTM professor receives Canada Gairdner Global Health Award

Sir Brian Greenwood, Manson Professor of Clinical Tropical Medicine at the London School of Hygiene & Tropical Medicine, has dedicated his career to saving children's lives by tackling malaria, meningitis and pneumonia - diseases which are dictated by the weather.

22 Mar 2012

Cote d'Ivoire working to rebuild health care system under new presidential administration

"Ten months after the West African country of Cote d'Ivoire started to emerge from a presidential election crisis during which almost all hospitals and clinics had to shut down for a good six months because they had been vandalized, looted and occupied, the new government under President Alassane Ouattara is trying to make public health care a priority," including implementing "a new national health regulation, which came into effect on Mar. 1, that offers free health services to pregnant women, children under five years and people suffering from malaria," Inter Press Service reports.

15 Mar 2012

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.

12 Mar 2012

Top-line results from Inviragen's INV21 Phase 1 trial on HFMD

Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.

12 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

Bacteria may be talking to each other with a contact-dependent language

What if bacteria could talk to each other? What if they had a sense of touch? A new study by researchers at UC Santa Barbara suggests both, and theorizes that such cells may, in fact, need to communicate in order to perform certain functions. The findings appear today in the journal Genes & Development.

2 Mar 2012

Breakthrough discovery about Rhizobium radiobacter

A new discovery involving two Simon Fraser University scientists could lead to a little known and benign bacterium becoming a vital new tool in the development of a vaccine against human immunodeficiency virus.

29 Feb 2012

USPTO issues two patents on 'Novel Shigella protein antigens and methods' to IVI

The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide.

27 Feb 2012

Intramuscular midazolam effective in treating status epilepticus

Drug delivery directly into muscle using an autoinjector is faster and may be more effective in stopping prolonged seizures, according to a study sponsored by the National Institutes of Health and conducted by a Wayne State University School of Medicine researcher.

17 Feb 2012

Benefits of long-term Kineret therapy in people with NOMID

A new study shows that Kineret (anakinra), a medication approved for the treatment of rheumatoid arthritis, is effective in stopping the progression of organ damage in people with neonatal-onset multisystem inflammatory disease.

13 Feb 2012

APP to launch Meropenem, Cilastatin and Imipenem in the U.S.

APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.

8 Feb 2012

Routine 4CMenB immunizations effective against meningococcal strains in infants

Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains and produced minimal interference with the response to the routine vaccinations, according to a study in the February 8 issue of JAMA.

8 Feb 2012

Tailoring TB treatment based on a patient's genetic sequence

A gene that influences the inflammatory response to infection may also predict the effectiveness of drug treatment for a deadly form of tuberculosis.

8 Feb 2012

Version of 'Goldilocks' gene could determine future treatment for TB patients

'Goldilocks' gene could determine best treatment for TB patients Tuberculosis patients may receive treatments in the future according to what version they have of a single 'Goldilocks' gene, says an international research team from Oxford University, King's College London, Vietnam and the USA.

3 Feb 2012

Researchers investigate Avian Pathogenic E. coli strains

Escherichia coli bacteria thrive in the lower intestine of humans and other animals, including birds. Most are vital constituents of the healthy gut flora, but certain forms of E. coli cause a range of diseases in both humans and poultry.

1 Feb 2012

Study investigates how bacteria change their disguise to evade vaccines

Genetics has provided surprising insights into why vaccines used in both the UK and US to combat serious childhood infections can eventually fail. The study, published today in Nature Genetics, which investigates how bacteria change their disguise to evade the vaccines, has implications for how future vaccines can be made more effective.

30 Jan 2012

New study aims to prevent bacterial infections in sub-Saharan African kids

Bacteria infections - most of which are preventable via vaccines readily available in the developed world - and not malaria are the leading cause of death for children in sub-Saharan Africa. A new Michigan State University project based in Nigeria and funded by a $5.8 million grant aims to help prevent these diseases by collecting local data on the ailments, spurring vaccine use and development. Funded by the Bill & Melinda Gates Foundation, the research led by Stephen Obaro focuses on diseases such as pneumonia, sepsis and meningitis.

25 Jan 2012